FDA Expands Pluvicto Approval for Metastatic Prostate Cancer Treatment

The FDA has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer. This decision significantly broadens the drug's application across all stages of PSMA-positive metastatic prostate cancer, potentially doubling the eligible patient population and advancing a new standard of care for patients battling this disease.